This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
The project is supported by PulsInvest AB to bring into commercialization.
The company?s proprietary non-fibrillogenic "A?CC technology" affords a unique approach to development of new therapies that are highly specific towards disease-driving oligomers.
Alzinova?s lead candidate is the peptide-based therapeutic vaccine ALZ-101. The development of this vaccine is supported by a Eurostars grant (a program powered by the European Community and EUREKA). The cost-efficient production and unique oligomer-targeting characteristics of this vaccine makes it likely to provide economic value against current and future standards of care.
Other developmental projects include the 100% A?42 oligomer-specific monoclonal antibody ALZ-201 (late discovery phase), and the replacement therapy peptide ALZ-301 (discovery phase).